The Biologic Importance of Tumor-infiltrating Lymphocytes
Overview
Authors
Affiliations
Detailed pathologic analysis has delineated a close association between intratumoral CD 8(+) cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the presence at tumor sites of negative immune regulatory elements, such as FoxP 3(+) T cells (Tregs) and PD-1/PD-L1 co-stimulatory molecules, is closely associated with inferior patient survival. Together, these results indicate the importance of the balance between cytotoxic and regulatory pathways in the tumor microenvironment as a critical determinant of prognosis. This immune index also provides a framework for devising therapeutic strategies to enlarge the population of antitumor cytotoxic T cells and attenuate immune regulation. Among these approaches, vaccination with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by antibody blockade of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) provides clinical benefits for some advanced-course melanoma patients. The extent of tumor necrosis in post-treatment biopsies is linearly related to the natural logarithm of the ratio of CD 8(+) T cells to FoxP 3(+) Tregs. These findings show a concordance between the immune signature of tumor protection in endogenous and therapy-induced responses, strongly supporting Martin Mihm's original insights.
Isik B, Davey M, Jaffer A, Buckley J, Baban C, Merrigan B Breast Cancer Res Treat. 2025; .
PMID: 39833654 DOI: 10.1007/s10549-025-07615-8.
Hu Y, Wang K, Chen Y, Jin Y, Guo Q, Tang H Front Immunol. 2024; 15:1430551.
PMID: 39050844 PMC: 11266158. DOI: 10.3389/fimmu.2024.1430551.
Immunotherapies for locally aggressive cancers.
Adams S, Nambiar A, Bressler E, Raut C, Colson Y, Wong W Adv Drug Deliv Rev. 2024; 210:115331.
PMID: 38729264 PMC: 11228555. DOI: 10.1016/j.addr.2024.115331.
Wang Y, Cai W, Xue Q, Zhang J, Zhou L, Xiong S Front Immunol. 2023; 14:1234894.
PMID: 37654479 PMC: 10465691. DOI: 10.3389/fimmu.2023.1234894.
Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff S, Shannon A, Pawlik T Int J Mol Sci. 2022; 23(22).
PMID: 36430440 PMC: 9698563. DOI: 10.3390/ijms232213961.